Navigation Links
Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
Date:9/10/2012

CRANBURY, N.J., Sept. 10, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).  Database lock is expected by the end of September and top-line trial results are expected in the first-half of next quarter.

"We are pleased to reach this important milestone of completing the patient treatment part of this comprehensive trial and look forward to compiling and analyzing the data," stated Carl Spana, Ph.D., President and CEO of Palatin. "Bremelanotide is the only on-demand treatment for FSD in clinical trials in the United States, and has the potential to transform the treatment of patients with FSD."

Approximately 400 premenopausal women, diagnosed with female sexual arousal disorder, hypoactive sexual desire disorder or both, were enrolled in the study.  Patients were treated for 16 weeks and were randomized to one of four double-blind treatment groups and received placebo or bremelanotide doses of 0.75, 1.25, or 1.75 milligrams.

The trial is a multi-centered, placebo-controlled, randomized, parallel-group trial designed to measure the safety and efficacy of subcutaneous (SC) bremelanotide doses intended for on-demand use in premenopausal females with FSD. The pharmacokinetics of SC bremelanotide will also be assessed during this trial.

The objectives of the Phase 2B trial are to demonstrate and identify safe and effective SC doses of bremelanotide and to define endpoint measurements to support transition to Phase 3 studies. Depending on the results of this trial, Phase 3 studies are anticipated to start in the second-half of calendar year 2013.

About Female Sexual Dysfunction

Female Sexual Dysfunction (FSD) is a multi-factorial condition that has anatomical, physiological, medical, psychologica
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
2. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
3. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
4. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
5. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
6. ICU Medical, Inc. Plans to "Vigorously Seek to Collect Damages" in wake of Patent Infringement Victory Over RyMed Technologies
7. BioStorage Technologies to Lead Discussion on the Value of a Comprehensive Sample Management Strategy
8. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
9. MedClean Technologies Announces 2011 Results
10. Patient Safety Technologies Reports First Quarter 2012 Results
11. Breathe Technologies Non-Invasive Open Ventilation (NIOV™) System Receives Medical Design Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... The Canadian Epilepsy Alliance (CEA) is thrilled to announce the ... about the most common neurological disorder in Canada ... series tells a fictional story based on the experiences of ... epilepsy. "Despite the fact that epilepsy affects ... and lack of awareness out there," says Gail Dempsey ...
(Date:8/21/2014)... N.Y. and HAMBURG, Germany , Aug. 21, 2014 ... is collaborating with Deutsches Elektronen-Synchrotron ( DESY ), a ... , to speed up management and storage of massive ... and Analytics architecture based on IBM software defined ... of data at peak performance and help scientists worldwide ...
(Date:8/21/2014)... announces the list of stocks featured in the Analyst Blog. ... news and events impacting stocks and the financial markets. Stocks ... - Free Report ), IBM (NYSE: IBM - Free ... Report ), GlaxoSmithKline plc (NYSE: GSK - Free Report ... Report ). Today, Zacks is promoting its ,Buy, ...
Breaking Medicine Technology:Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11
... Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO ) today ... Total revenue was $2.6 million and $8.2 million for the ... million and $3.8 million for the same periods in 2010. ... September 30, 2011, were $9.0 million and $24.0 million as compared ...
... UCB today announced new ... (certolizumab pegol) was associated with a rapid and sustained ... of moderate to severe rheumatoid arthritis (RA) patients. The ... 2011 Annual Scientific Meeting in Chicago, November 5-9, are ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 9New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 2New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 3New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 4New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 5New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 6New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 7New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 8New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 9New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 10New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 11
(Date:8/21/2014)... FL (PRWEB) August 21, 2014 The ... published today in The Journal of the American Medical ... more invasive cancers and reduces unnecessary recalls. Memorial Healthcare ... in the study. , “This study confirms what we ... invasive, harmful cancers we want to find and, at ...
(Date:8/21/2014)... The second bellwether trial involving ... has begun in Massachusetts state court. The device ... Law Group LLP, a national personal injury law ... stemming from the implantation of mesh products, provides ... injuries suffered at http://www.wehelpwomen.com/transvaginal-mesh/ . , Maria ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The ... this year's conference will focus on the Future ... for research, innovation and commercialization. , With the ... SALSS combines the worlds' of business and science. ... widely recognized Summit, gathering a diverse community with ...
(Date:8/21/2014)... two types of polio vaccines seems to provide stronger ... eradicate polio, a new study shows. The research ... the Salk inactivated poliovirus vaccine (IPV) to those who ... vaccine (OPV) appeared to improve their immunity to the ... the Aug. 22 issue of the journal Science ...
(Date:8/21/2014)... 21, 2014. Researchers have published a study examining ... patients with motor complete spinal cord injury (SCI). ... at discharge and follow-up among patients with motor ... on August 2 by the Archives of ... included small but significant differences in self-care and ...
Breaking Medicine News(10 mins):Health News:Dr. Mary Hayes: Study Shows 3D Mammography Finds More Invasive Cancers While Reducing Unnecessary Recalls 2Health News:Transvaginal Mesh Lawsuit News: Second Boston Scientific Mesh Bellwether Trial Begins, The Rottenstein Law Group LLP Reports 2Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2Health News:Two Polio Vaccines May Give Greater Protection Against Crippling Disease 2Health News:Researchers examine impact of race and ethnicity in motor complete spinal cord injury 2
... with a low-priced antibiotic, according to scientists.It causes severe ... team of scientists at the Liverpool School of Tropical ... in the advanced stages of the disease. In addition, ... Filariasis (LF) affects nearly 120 million people, usually, in ...
... Shepherd Medical Center in Oregon is providing healthy organic food ... Foods from wild salmon to local organic foods are there ... of antioxidant-rich dried cherries. , Angela Mallory, a ... for five days recently for the delivery of her son ...
... is tougher to quit menthol cigarettes than the regular ones, ... in blacks in the U.S.// ,This study was ... black smokers go for menthol cigarettes like Kool or Newport ... several historical and cultural reasons, according to the study. This ...
... increased homicide rates. However as the membership of Alcoholics Anonymous ... number of homicides. In males who consume beer and spirits, ... homicide, a new study finds. ,Results are published ... ,"It is important to try to understand the ...
... Health Department today clarified that so far no chikungunya ... Services T.K. Kuttamani said //that three death attributed to ... ,Mukundan, 71 at Vavallichira, Cherthala ded from ... Selvi, 81, of Kollekkattu also died of natural causes. ...
... the University of Virginia Health System have identified, for the ... carry the genes for nicotine// dependence (ND) in an African ... linkage and included the largest group of African Americans to ... participants in research to find genetic links to ND have ...
Cached Medicine News:Health News:Menthol cigarettes harder to quit than regular cigarettes 2Health News:Alcoholics Anonymous: A Blessing For The Addicted 2Health News:Alcoholics Anonymous: A Blessing For The Addicted 3Health News:Researchers Locate Genetic Link for Nicotine Dependence Among African Americans 2
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... procedurally specific tip configurations provide maximum ... to all areas of the meniscus ... Graspers feature an infinite position sliding-lock ... tearing or slipping even in ...
... procedurally specific tip configurations provide maximum ... to all areas of the meniscus ... Graspers feature an infinite position sliding-lock ... tearing or slipping even in ...
Medicine Products: